Cargando…
Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study
BACKGROUND: C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to the rarity of the disease, observational dat...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832765/ https://www.ncbi.nlm.nih.gov/pubmed/36631797 http://dx.doi.org/10.1186/s12882-023-03058-9 |